Overview

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

Phase I, open label, non-randomized, multicenter, prospective dose escalation study of F16IL2 in combination with very low-dose cytarabine in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT).

Phase:

Phase 1

Details

Lead Sponsor:

Philogen S.p.A.

Treatments:

Antibodies
Antibodies, Monoclonal
Cytarabine
Interleukin-2